MedTrace Logo

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease

NCT01168596 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-01-10

Study results available
· View outcomes & findings →

Summary

The purpose of the research study is to determine if rasagiline is an effective treatment for fatigue in patients with Parkinson's disease (PD).

Conditions

Interventions

DRUG

Rasagiline

Comparison of Rasagiline versus placebo. Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.

DRUG

Placebo

Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Irene A Malaty, MD · University of Florida Department of Neurology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168596 on ClinicalTrials.gov